IVERIC bio, Inc. (NASDAQ:ISEE) Shares Acquired by Arizona State Retirement System

Arizona State Retirement System grew its holdings in IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) by 10.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 21,693 shares of the company’s stock after buying an additional 2,097 shares during the quarter. Arizona State Retirement System’s holdings in IVERIC bio were worth $365,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale increased its stake in IVERIC bio by 2.9% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 28,800 shares of the company’s stock valued at $466,000 after purchasing an additional 800 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in IVERIC bio by 36.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,230 shares of the company’s stock valued at $54,000 after purchasing an additional 870 shares in the last quarter. Altium Capital Management LP increased its stake in IVERIC bio by 0.3% in the 4th quarter. Altium Capital Management LP now owns 329,101 shares of the company’s stock valued at $5,503,000 after purchasing an additional 1,000 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in IVERIC bio in the 4th quarter valued at approximately $40,000. Finally, State Board of Administration of Florida Retirement System increased its stake in IVERIC bio by 18.9% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 22,463 shares of the company’s stock valued at $376,000 after purchasing an additional 3,565 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ISEE. Credit Suisse Group raised their price target on IVERIC bio to $24.00 in a research report on Friday, May 20th. Morgan Stanley raised their price target on IVERIC bio from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, July 7th. B. Riley began coverage on IVERIC bio in a research report on Thursday, May 12th. They set a “neutral” rating and a $12.00 price target for the company. Stifel Nicolaus raised their price target on IVERIC bio from $22.00 to $28.00 in a research report on Wednesday, May 4th. Finally, Bank of America began coverage on IVERIC bio in a research report on Wednesday, June 8th. They set a “buy” rating and a $18.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.20.

Insider Activity at IVERIC bio

In related news, EVP Anthony S. Gibney sold 7,791 shares of IVERIC bio stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $9.41, for a total value of $73,313.31. Following the transaction, the executive vice president now owns 10,959 shares in the company, valued at $103,124.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Calvin W. Roberts acquired 25,000 shares of IVERIC bio stock in a transaction on Monday, June 13th. The shares were bought at an average price of $9.62 per share, for a total transaction of $240,500.00. Following the completion of the purchase, the director now directly owns 32,500 shares in the company, valued at approximately $312,650. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Anthony S. Gibney sold 7,791 shares of the business’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $9.41, for a total value of $73,313.31. Following the transaction, the executive vice president now owns 10,959 shares in the company, valued at approximately $103,124.19. The disclosure for this sale can be found here. 2.70% of the stock is owned by insiders.

IVERIC bio Stock Up 4.0 %

ISEE stock opened at $11.45 on Thursday. IVERIC bio, Inc. has a 52-week low of $8.37 and a 52-week high of $19.34. The stock’s fifty day simple moving average is $10.58 and its 200-day simple moving average is $13.20. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -9.39 and a beta of 1.51.

IVERIC bio (NASDAQ:ISEEGet Rating) last issued its earnings results on Tuesday, July 26th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). During the same quarter in the previous year, the business posted ($0.32) earnings per share. As a group, analysts anticipate that IVERIC bio, Inc. will post -1.49 earnings per share for the current fiscal year.

IVERIC bio Company Profile

(Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Read More

Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio, Inc. (NASDAQ:ISEEGet Rating).

Institutional Ownership by Quarter for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.